康哲药业宣布,其芦可替尼乳膏新增适应症(特应性皮炎)的上市申请已获中国国家药品监督管理局正式受理,并被纳入优先审评程序。此举有望加速该产品在中国市场的准入进程,为特应性皮炎患者提供新的治疗选择。
康哲药业宣布,其芦可替尼乳膏新增适应症(特应性皮炎)的上市申请已获中国国家药品监督管理局正式受理,并被纳入优先审评程序。此举有望加速该产品在中国市场的准入进程,为特应性皮炎患者提供新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.